



Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

August 6, 2019

BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the **2019 Wedbush PacGrow Healthcare Conference** in New York City. The presentation is scheduled for Wednesday, August 14 at 1:20 p.m. Eastern Time.

The Wedbush presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). The presentation will also be available on the Sangamo website after the event.

Earlier in the week, Dr. Macrae will participate in the **BTIG Biotechnology Conference 2019** in a panel discussion, "Exploring the Novel Approaches to Treating Sickle Cell Disease". This event is scheduled for Monday, August 12 at 1:00 p.m. Eastern Time. No webcast is available for the BTIG event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, *ex vivo* gene-edited cell therapy, and *in vivo* genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190806005815/en/>

Source: Sangamo Therapeutics, Inc.

Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com

Media Inquiries – Global
Aron Feingold
510-970-6000, x421
afeingold@sangamo.com

Investor Relations and Media Inquiries – European Union & United Kingdom
Caroline Courme
33 4 97 21 27 27
ccourme@sangamo.com